239 related articles for article (PubMed ID: 31803506)
21. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
22. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
[TBL] [Abstract][Full Text] [Related]
24. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
25. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
26. Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services.
Walker A
J Oncol Pharm Pract; 2020 Dec; 26(8):2015-2019. PubMed ID: 32957860
[TBL] [Abstract][Full Text] [Related]
27. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
28. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
29. Revisiting NTRKs as an emerging oncogene in hematological malignancies.
Joshi SK; Davare MA; Druker BJ; Tognon CE
Leukemia; 2019 Nov; 33(11):2563-2574. PubMed ID: 31551508
[TBL] [Abstract][Full Text] [Related]
30. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
31. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
32. On the right TRK: from oncogene discovery to cancer therapeutics.
Barbacid M
Ann Oncol; 2019 Nov; 30 Suppl 8(Suppl 8):viii3-viii4. PubMed ID: 32223936
[No Abstract] [Full Text] [Related]
33. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
34. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
35. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
36. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
37. Tropomyosin receptor kinases in sarcomas - of joy and despair.
Dieckmann N; Schildhaus HU; Bauer S
Curr Opin Oncol; 2021 Jul; 33(4):336-344. PubMed ID: 33989242
[TBL] [Abstract][Full Text] [Related]
38. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
39. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
[TBL] [Abstract][Full Text] [Related]
40. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
Harada G; Drilon A
Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
